Menu Search
Equities

Shanghai Henlius Biotech Inc

2696:HKG.HS

Shanghai Henlius Biotech Inc

Actions
  • Price (HKD)18.84
  • Today's Change0.00 / 0.00%
  • Shares traded0.00
  • 1 Year change+73.48%
  • Beta--
Data delayed at least 15 minutes, as of May 28 2024.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Shanghai Henlius Biotech Inc. is a China-based company principally involved in the research, development, production and sales of monoclonal antibody products. The Company’s main products include rituximab injection HLX01 (Hanlikang), Herceptin (trastuzumab) biosimilar HLX02, Humira (adalimumab) biosimilar HLX03 and Avastin (bevacizumab) biosimilar HLX04, as well as bio-innovative drug candidates, including HLX06 (a novel VEGFR2 inhibitor), HLX07 (an EGFR inhibitor), HLX10 (a novel PD-1 inhibitor), HLX20 (a novel PD-L1 inhibitor) and HLX22 (a novel HER2 inhibitor), among others. The Company is also engaged in the provision of related technical services. The Company operates its businesses primarily in Mainland China and the United States.

  • Revenue in HKD (TTM)5.81bn
  • Net income in HKD588.43m
  • Incorporated2010
  • Employees3.64k
  • Location
    Shanghai Henlius Biotech IncBuilding CNo. 1289 Yishan Road, Xuhui DistrictSHANGHAI 200233ChinaCHN
  • Phone+86 2 133395800
  • Fax+86 2 134611802
  • Websitehttps://www.henlius.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.